Autopsy report · NCT03819660

Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3

“Development of indication not being pursued”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 6 months before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 2 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Catalyst Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Spinal Muscular Atrophy Type 3

Interventions

Amifampridine Phosphate 10 MG Oral Tablet

Participants

13

Sites

1

Countries

Italy

Trials that died the same way

• Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma
  “Current study design couldn't support futher development on this indication” (59% match in meaning)
• Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
  “company did not pursue this indication” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.